The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Use of KMT2 family mutations to define a distinct epithelial-high, stromal-depleted, and interferon-active gene expression state in colorectal cancer.
 
Songwit Payapwattanawong
No Relationships to Disclose
 
Jessica Lal
No Relationships to Disclose
 
Yixin Xu
No Relationships to Disclose
 
Kangyu Lin
No Relationships to Disclose
 
Emerik Osterlund
Honoraria - Amgen
Consulting or Advisory Role - Amgen
Research Funding - Amgen (Inst); Lilly (Inst); Merck KGaA (Inst); Nordic Drugs (Inst); Roche (Inst); Sanofi (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Amgen; Merck KGaA; Nordic Drugs
 
Cynthia Yeung
No Relationships to Disclose
 
Berta Martin
No Relationships to Disclose
 
Kathryn Aziz
Employment - MD Anderson Cancer Center
 
Kristin Alfaro
No Relationships to Disclose
 
Giulia Maddalena
No Relationships to Disclose
 
Guglielmo Vetere
No Relationships to Disclose
 
Arvind Dasari
Consulting or Advisory Role - HutcMed; Illumina/GRAIL; Personalis; SIRTIS; Takeda
Research Funding - Eisai (Inst); Guardant Health (Inst); Hutchison MediPharma (Inst); Merck (Inst); Natera (Inst); XENCOR (Inst)
Travel, Accommodations, Expenses - Hutchison MediPharma; Takeda
 
Christine Parseghian
Consulting or Advisory Role - Amgen; Johnson & Johnson/Janssen
Research Funding - BioMed Valley Discoveries; Lilly; Verastem
 
Jason Willis
Honoraria - Bayer; Cor2Ed
Consulting or Advisory Role - Healios, K.K.; TME Therapeutics
 
John Paul Shen
No Relationships to Disclose
 
Michael Overman
Consulting or Advisory Role - 3T BioSciences; Agenus; Bristol-Myers Squibb; Eisai; Janssen; Merck; Pfizer; Roche/Genentech; Simcere; Summit Therapeutics
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
Kanwal Raghav
Honoraria - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding - Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
 
Van Morris
Consulting or Advisory Role - Abbvie; BioNTech SE; Bristol-Myers Squibb/Celgene; Exelixis; GlaxoSmithKline; Incyte; Pfizer
Research Funding - Bicara Therapeutics (Inst); BioNTech (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst)
 
Kunal Rai
No Relationships to Disclose
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Lutris; Navire
Consulting or Advisory Role - Alentis Therapeutics; AmMax Bio; Arcus Biosciences; AstraZeneca; AVEO; BeiGene; BioNTech SE; Boehringer Ingelheim; Bristol-Myers Squibb/Medarex; Carina Biotech; Clasp Therapeutics; Cytovation; Dewpoint Therapeutics; EMD Serono; Erasca, Inc; Flame Biosciences; Frontier Medicines; Genentech; Harbinger Oncology, Inc; Ikena Oncology; Iterion Therapeutics; Kivu Biosciences; Marengo Therapeutics; Pfizer; Regeneron; Roche; SageMedic; SERVIER; Shionogi; T-Cypher Bio; Tachyon Therapeutics; Transcode; XAIRA Therapeutics; Zentalis; Zentalis
Research Funding - Boehringer Ingelheim; EMD Serono; Genentech; Pfizer; Roche; Zentalis